Photo by ospanali from unsplash
Psoriasis is one of the immune‐mediated inflammatory diseases where CD4+ T lymphocytes, mainly Th1 cells, and B lymphocytes contribute in their pathogenesis through a pro‐inflammatory effect, production of antibodies, activation… Click to show full abstract
Psoriasis is one of the immune‐mediated inflammatory diseases where CD4+ T lymphocytes, mainly Th1 cells, and B lymphocytes contribute in their pathogenesis through a pro‐inflammatory effect, production of antibodies, activation of T cells and cytokine synthesis. B and T lymphocyte attenuator (BTLA) is a co‐inhibitory molecule expressed on T and B lymphocytes as well as other immune cells, and it is necessary to inhibit homoeostatic expansion and activation of lymph node and skin‐resident γδ T cells. BTLA expression is regulated by RORγt and IL‐7. The study aimed at adding more insight on the role played by co‐inhibitory molecule BTLA in psoriasis vulgaris and its inter‐relation with RORγt and IL‐7 to establish a basis for novel treatment strategies.
Journal Title: Australasian Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!